Spots Global Cancer Trial Database for pik3ca
Every month we try and update this database with for pik3ca cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Adjuvant Aspirin Treatment for Colon Cancer Patients | NCT02467582 | Colon Cancer | Aspirin Placebo | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy | NCT02957266 | Cervical Cancer | Volumetric Arc ... Interstitial br... Cisplatin Gemcitabine PIK3CA KRAS BRAF RRM1 | 18 Years - 70 Years | The National Center of Oncology, Azerbaijan | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | NCT01633060 | Metastatic Brea... | Fulvestrant BKM120 BKM120 matching... | 18 Years - | Novartis | |
| CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer | NCT02861300 | Colorectal Canc... Colon Cancer Rectal Cancer Solid Tumor | CB-839 Capecitabine | 19 Years - | Case Comprehensive Cancer Center | |
| Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | NCT04586335 | Ovarian Cancer Breast Cancer Solid Tumor Prostate Cancer Endometrial Can... | CYH33 | 18 Years - | Haihe Biopharma Co., Ltd. | |
| Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. | NCT04586335 | Ovarian Cancer Breast Cancer Solid Tumor Prostate Cancer Endometrial Can... | CYH33 | 18 Years - | Haihe Biopharma Co., Ltd. | |
| The Oncopanel Pilot (TOP) Study | NCT02171286 | Colorectal Canc... Advanced Non-Sm... Advanced Melano... Gastrointestina... Patients With D... | 18 Years - | British Columbia Cancer Agency | ||
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant | NCT04899349 | Breast Cancer | Alpelisib Fulvestrant Metformin XR Dapagliflozin +... Dapagliflozin | 18 Years - | Novartis | |
| Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | NCT04997902 | HNSCC | Tipifarnib Alpelisib | 18 Years - | Kura Oncology, Inc. | |
| PIK3CA in HER2+ BC and pCR Trial | NCT05750693 | HER2-positive B... | PIK3CA analysis | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | |
| Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant | NCT04899349 | Breast Cancer | Alpelisib Fulvestrant Metformin XR Dapagliflozin +... Dapagliflozin | 18 Years - | Novartis | |
| Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer | NCT01449370 | Metastatic Soli... | TAK-117 | 18 Years - | Takeda | |
| National Evaluation of Patients With PIK3CA-Related Overgrowth Spectrum (PROS) | NCT05563831 | PIK3CA-related ... CLOVES Syndrome Klippel Trenaun... Megalencephaly MCAP Macrodactyly Vascular Malfor... Lymphatic Malfo... Venous Malforma... | national regist... | - | Institut National de la Santé Et de la Recherche Médicale, France | |
| A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation | NCT01572727 | Breast Cancer | Paclitaxel BKM120 matching... BKM120 | 18 Years - | Novartis | |
| Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies | NCT03317366 | Proteus Syndrom... PIK3CA-Related ... Growth Disorder... | ARQ 092 | 2 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| PIK3CA in HER2+ BC and pCR Trial | NCT05750693 | HER2-positive B... | PIK3CA analysis | 18 Years - | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
